Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Editas Medicine, Inc. - Common Stock
(NQ:
EDIT
)
3.240
+0.040 (+1.25%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 30, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Editas Medicine, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Wednesday's session: gap up and gap down stocks
↗
August 13, 2025
Let's have a look at what is happening on the US markets on Wednesday. Below you can find the gap up and gap down stocks in today's session.
Via
Chartmill
Editas Medicine Inc (NASDAQ:EDIT) Reports Mixed Q2 2025 Earnings: Revenue Beat but Wider Loss
↗
August 12, 2025
Editas Medicine posted Q2 2025 revenue of $3.58M, beating estimates, but EPS loss widened to -$0.63. Stock dipped 1.75% amid restructuring concerns. Pipeline progress includes IND filing plans for...
Via
Chartmill
Editas Medicine Announces Second Quarter 2025 Results and Business Updates
August 12, 2025
From
Editas Medicine, Inc.
Via
GlobeNewswire
Can This Beaten-Down Stock Bounce Back?
↗
August 12, 2025
This small-cap biotech is seeking to develop breakthrough therapies, but so far it's found little success.
Via
The Motley Fool
Earnings Scheduled For May 12, 2025
↗
May 12, 2025
Via
Benzinga
Peering Into Editas Medicine's Recent Short Interest
↗
February 25, 2025
Via
Benzinga
Wall Street Expects Editas Medicine to Soar 53%. Is It Time to Buy Now?
↗
June 28, 2025
Via
The Motley Fool
Topics
Workforce
2 Beaten-Down Stocks to Avoid
↗
June 27, 2025
Via
The Motley Fool
Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst
↗
June 18, 2025
Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a tough funding climate.
Via
Benzinga
Editas Medicine Is Great. Here's Why You Shouldn't Buy It.
↗
June 17, 2025
Via
The Motley Fool
Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover
↗
June 17, 2025
The companies were already collaborating on a handful of cardiovascular-focused gene-editing treatments.
Via
Investor's Business Daily
Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June
June 12, 2025
From
Editas Medicine, Inc.
Via
GlobeNewswire
1 Stock Down 97% That Could Double, According to Wall Street
↗
May 25, 2025
Via
The Motley Fool
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
May 21, 2025
Via
Benzinga
Editas Medicine: A Cautionary Tale for Investors
↗
May 15, 2025
Via
The Motley Fool
Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June
May 14, 2025
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas’ Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting
May 14, 2025
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting
May 13, 2025
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Announces First Quarter 2025 Results and Business Updates
May 12, 2025
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR Patent Interference to Patent Trial and Appeal Board
May 12, 2025
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in May
May 05, 2025
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
April 28, 2025
From
Editas Medicine, Inc.
Via
GlobeNewswire
The Future of Healthcare: 10 Predictions For The Next Decade
March 27, 2025
The healthcare industry stands on the brink of a transformative decade, driven by rapid advancements in technology, shifting demographics, and evolving patient expectations. Over the next ten years, we...
Via
MarketMinute
Topics
Artificial Intelligence
Editas Medicine Announces Chief Financial Officer Transition
March 20, 2025
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Stock Slides After-Hours On Bigger-Than-Expected Q4 Loss, But Retail Bulls Eye M&A Potential
↗
March 05, 2025
The company expects its current cash position and retained portions of payments from its agreement with Vertex to support operations into the second quarter of 2027.
Via
Stocktwits
Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates
March 05, 2025
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March
February 24, 2025
From
Editas Medicine, Inc.
Via
GlobeNewswire
Earnings Scheduled For March 5, 2025
↗
March 05, 2025
Via
Benzinga
What's going on in today's session
↗
February 20, 2025
Intrigued by the market activity one hour before the close of the markets on Thursday? Uncover the key winners and losers of today's session in our insightful analysis.
Via
Chartmill
Top movers in Thursday's session
↗
February 20, 2025
Stay up-to-date with the latest market trends in the middle of the day on Thursday. Explore the top gainers and losers during today's session in our detailed report.
Via
Chartmill
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
